tirzepatide off shortage list FDA says this weight loss drug is over, but patients worry about cost and availability The Tirzepatide Shortage Is Over:

What affects tesamorelin before and after results

It is illegal to purchase, sell and possess peptides, in the Australian Capital Territory, without a prescription or lawful authority

Brand-Name Pricing (2026) Mounjaro (Diabetes Indication): List price: $1,069/month ($12,828/year) Without insurance: Pay full price With insurance: $25-$300/month copay (if covered) Availability: On shortage list periodically Zepbound (Weight Loss Indication): List price: $1,069/month ($12,828/year) Without insurance: Pay full price With insurance: $25-$300/month copay (if covered) Availability: Limited, shortage issues Manufacturer Savings Cards: Eli Lilly offers savings card Reduces cost to $25-$50/month Requirements: Commercial insurance (not Medicare/Medicaid) Exclusions: Cash-pay patients ineligible Income limits: May apply For uninsured or underinsured patients, brand-name is unaffordable at $1,069/month

Neuroendocrinology Letters

10.1021/jm049924d 44